Matthew Plaud on Building Supply Chains that Actually Scale
In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.
The discussion focused on something many teams today are feeling firsthand: what gets a therapy through early clinical work isn’t what carries forward at scale. As patient volumes grow, small inefficiencies don’t stay small; they compound (and variability creeps in).
Matthew speaks to that shift, framing it less as a logistics problem and more as a design gap. Supply chains are often built around direct milestones without enough attention to how those pieces behave together over time. As a result, when therapies begin to scale, that fragmentation only becomes harder to manage. He highlights the need to think in terms of lifecycle much earlier than many organizations are used to. Decisions made upstream about how materials are handled and how partners and vendors interact don’t stay isolated. They shape how resilient the supply chain remains months or years later, as programs progress from early clinical trials into global commercialization.
He also highlights the growing expectation for transparency across the supply chain. With patient-specific therapies, there is no room for ambiguity. Teams need audit-ready documentation that demonstrates where materials are (and where they have been) and the conditions they’ve been exposed to. They can’t chase disconnected data across different systems without introducing risk.
The conversation reflects what developers are seeing as more programs reach moments of scale as they move closer to commercialization. It highlights the need for tighter integration, earlier alignment, and infrastructure that can absorb complexity without breaking under it.
Read the full interview here:
From Logistics to Lifecycle: Building Advanced Therapy Supply Chains that Scale (Contract Pharma)
